Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 16Colorectal Neoplasms 7Small Cell Lung Carcinoma 4Neoplasm Metastasis 4Stomach Neoplasms 3Recurrence 3Biliary Tract Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Triple Negative Breast Neoplasms 1Somatostatinoma 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Rectal Neoplasms 1Rectal Cancer Patients 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Non-resectable 1Pancreatic Cancer Metastatic to Liver 1Pancreatic Adenocarcinoma 1PDAC - Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Neoplasms 1Neoadjuvant Chemotherapy 1Metastatic Pancreatic Adenocarcinoma 1Locally Advanced Rectal Cancer (LARC) 1

Interventions

Gemcitabine 45Cisplatin 34Oxaliplatin 23Capecitabine 17Fluorouracil 13Leucovorin 12pembrolizumab 11lenvatinib 11durvalumab 10S 1 (combination) 10Irinotecan 10Bevacizumab 8apatinib 7Nivolumab 7tremelimumab 6Trastuzumab 5envafolimab 4atezolizumab 4Injections 4Docetaxel 4trametinib 3titanium silicide 3tislelizumab 3irinotecan sucrosofate 3camrelizumab 3Radiotherapy 3Drug Therapy 3zanidatamab 2toripalimab 2surufatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Biliary Tract Neoplasms × irinotecan sucrosofate × Clear all
NCT06219941 2026-02-12

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

AstraZeneca

Phase 2 Recruiting
224 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Stomach Neoplasms

NCT04005339 2026-01-26

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Georgetown University

Phase 2 Active not recruiting
48 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gastrointestinal Neoplasms

NCT03524508 2022-08-24

Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer

Asan Medical Center

Phase 2 Completed
178 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡